AZD-5069 是有效的 CXCR2 chemokine 受体拮抗剂，用于癌症的研究。 Targets CXCR2 In vitro AZD5069 is a slowly reversible antagonist of CXCR2 with effects of time and temperature evident on the pharmacology and binding kinetics. In vivo In preclinical models, airway neutrophil recruitment in response to inflammatory challenge is abrogated by selective targeting of CXCR2 using AZD5069.